✨ Only 100 days until the inaugural 2026 ISGD Clinical Trials Summit! We’re spotlighting our outstanding Program Advisory Committee, whose expertise is shaping an exciting, forward-thinking program. Join us in Galveston! 🌎 🧬 Register Now: www.is-gd.org/2026-cts @tobias-b-huber.bsky.social

🚨 The countdown is on! August 1 is your last chance to save with early registration and submit your abstract for the inaugural ISGD Clinical Trials Summit, hosted by UTMB. Join us Nov. 13–15 in Galveston, TX. 🔗 Register: www.is-gd.org/2026-cts ➤ Submit your abstract: www.is-gd.org/cts-2026-abs...

🚨 August 1 is almost here! Register early and submit your abstract for the 2026 ISGD Clinical Trials Summit, hosted by UTMB. Join leading experts in glomerular disease Nov. 13–15 in Galveston, TX! Register today: www.is-gd.org/2026-cts Submit an Abstract: www.is-gd.org/cts-2026-abs...

🎙️New #GNin10 Ready to level up your MN knowledge from IgG1 to IgG4? 🧬 In our latest Board Review Bonus, Dr. Kenar Jhaveri & Dr. Koyal Jain break down Membranous Nephropathy—from biopsy "spikes" to the "Koyal-Kenar" risk criteria! 🎧 share.transistor.fm/s/03967a4b ⛱️ PARASOL-MN: is-gd.org/parasol

🍁 We wrapped up June with another ISGD Preceptorship at @uoftmedicine.bsky.social! Thanks Arenn Jauhal & Heather Reich for a fascinating 2-day program on complement-mediated GD! Learned so much & worked on solving so many problems 🍁 The GD patients of Canada are in very good hands!

When we say the International Society of Glomerular Disease, we mean INTERNATIONAL. 🌍 In partnership with UTMB, the inaugural ISGD Clinical Trials Summit 2026 brings together speakers from 12+ countries and scholarship applicants from 5+ countries. Register now: www.is-gd.org/2026-cts #ISGD #UTMB

📢 Abstract deadline extended! Submit your work to ISGD's Inaugural Clinical Trials Summit by August 1, 2026. Share innovations in kidney disease clinical trials, biomarkers, patient engagement, trial design and more! 🔗 www.is-gd.org/cts-2026-abs... #ISGD #KidneyResearch @tobias-b-huber.bsky.social

💗 Congrats to @tobias-b-huber.bsky.social, honored with this year's Münster Heart Center Lecture! 🫀 A well-deserved recognition of the vital link between kidney & heart health. He also signed Münster’s historic Golden Book in the Hall of Peace, joining the likes of Obama, the Dalai Lama & QEII 📖

🚨New GN in 10🎙️ Think Alport's only affects males 🧬? Think again! @kdjhaveri.bsky.social & Koyal Jain provide a comprehensive clinical overview of hereditary nephritis—aka Alport syndrome. 🎧 Listen here: share.transistor.fm/s/434d7408 #AlportSyndrome #ISGD #GNin10 @tobias-b-huber.bsky.social

🔬 Join leading experts at ISGD’s first Clinical Trials Summit this November! Explore the latest in GD regulatory advances, patient engagement, biomarkers, and recruitment strategies! 🗓️ Nov 13–15, 2026 📍 Galveston, TX 🔗 www.is-gd.org/2026-cts #ISGD #ClinicalTrials @tobias-b-huber.bsky.social

#ERA26 🏴󠁧󠁢󠁳󠁣󠁴󠁿✨ Challenging our thinking in nephrology and in glomerular diseases. Proud to see many members taking center stage. The ISGD team was grateful to spend time with so many of our members and partners committing to better outcomes and lives for our patients. #GlomerularDisease #KidneyHealth

Starting the week with an ISGD Preceptorship at the UK’s National Renal Complement Therapeutics Centre 🤩 @newcastleuni.bsky.social

🚨 Late-Breaking Abstract Submissions are open for the 2026 ISGD Clinical Trials Summit! Share your findings with the global glomerular disease research community. 🗓️ Nov 13–15, 2026
📍 Galveston, TX Submit: www.is-gd.org/cts-2026-abs...
 Register: www.is-gd.org/2026-cts @tobias-b-huber.bsky.social

The updated ISGD Clinical Trials Summit Agenda Highlights are here! FDA panels, patient voices, late-breaking research, trial innovation, and more! @tobias-b-huber.bsky.social 🗓️ Nov 13–15, 2026 📍Galveston, TX Register: www.is-gd.org/2026-cts #ISGD #ClinicalTrials #Nephrology #KidneyResearch

New GN in 10 Board Review Bonus! 🎧 Hosts @kdjhaveri.bsky.social & Dr. Koyal Jain tackle the complexities of Kidney Amyloidosis. From "mushy" microscopy to the precision of mass spectrometry, this episode is a must-listen for the global #NephTwitter community. Listen here: bit.ly/4cIvNkP

The time is finally here: A sneak peek of the Agenda Highlights for ISGD’s 2026 Clinical Trial Summit with UTMB, bringing together leaders advancing glomerular disease research. Join us Nov. 13–15, 2026 in Galveston, TX. Register: www.is-gd.org/2026-cts Questions/sponsorship: ctsummit@is-gd.org

Thank you to these podcasts on #NephMadness 2026: - GN in Ten @isgd.bsky.social - Global Kidney Care @theisn.org - @freelyfiltered.bsky.social - @febrilepodcast.com - @nkf-professionals.bsky.social - @coreimpodcast.bsky.social - Nephron Segment bit.ly/NM26podcrawl

More than 100 years after #FSGS was first described, we have the first FDA-approved treatment. A proud day for the collaborative #ParasolProject! With the global community uniting to transform glomerular health, this is only the beginning. ⛱️

A Milestone for FSGS — And a Proud Moment for PARASOL

A historic milestone for FSGS patients as the FDA approves the first drug for the condition, highlighting the collaborative efforts behind the PARASOL project's success.

is-gd.org

♨️ Debate at WCN26: Should complement inhibition be considered before targeted-release budesonide in patients with IgAN at risk of progression? A key discussion between upstream vs downstream treatment strategies in IgAN. 🧵(1) #ISNWCN #GlomerularDisease

#ISNWCN “KDIGO IgAN Session” discussing so interesting cases and perspectives 🇺🇸🇨🇳🇯🇵 🔎Effect of therapies on GFR loss and proteinuria 🎯Novel agents 👉🏻Disease activity and clinical background are important to determine appropriate therapy #GlomerularDisease #KidneyHealthMatters 🌎🫘🌸

“Understanding and Treating Complement-Mediated Glomerular Disease” #ISNWCN #ISGD ✅KPMP: right treatment, right person, right time 🧬Haplotype and Disease Penetrance- Genetic testing ❌C5b-9: more severe disease 🖊️C5a in AAV - complement therapies 🎯”RESET into homeostasis” #GlomerularDisease

🌟 Enjoying our #WCN2026 coverage? A heartfelt thank you to our incredible ISGD social media ambassadors, Dr. @gabyneph.bksy.social and Dr. Belén Gallegos, for bringing us the latest updates and insights in glomerular disease and keeping our community informed and engaged 🙌 #ISGD #GlomerularDisease

Applications are open for the next class of the #NephJC internship Apply here www.nephjc.com/news/nephjc-... or scan the QR code #ISNWCN

⛩️ Together in Yokohama at #ISNWCN with presidents of ERA, @theisn.org and @isgd.bsky.social ! ⛩️ @rosertorra.bsky.social, Marcello Tonelli, and @tobias-b-huber.bsky.social + Ron Gansevoort

At WCN’26, Tobias Huber highlighted the mission of the ISGD: uniting a 🌎 community to connect, educate, and advance research to improve care for patients with #GlomerularDisease With 1,700+ members across 102 countries, #ISGD is building a 🌎 network for innovation and collaboration in 🫘 disease

Heather Reich ISGD Chair of the Membership & Accreditation Committee, is present at the WCN’26 🤩 A great session about exploring the role of APRIL in IgAN 👉🏻 A great discussion of clinical scenarios #ISGD #GlomerularDisease #ISNWCN

Amazing! Paola Romagnani #ISGD #ISNWCN with “Podocytopathies: Knowns and Unknowns” 👉🏻Podocyte loss and regeneration 👀Autoimmune, genetic, adaptive, infectious, toxic, monoclonal 🎯Anti-slit autoantibodies-> ⬇️ prognosis #GlomerularDisease #Yokohama 🌸

Our ISGD president Tobias Huber is present at the WCN’26 🌸 👉🏻 His first session of the day: Kidney tissue-specific gene targeting 🦠 Adenovirus as a potential vector for gene targeting therapies #ISNWCN #GlomerularDisease #ISGD

🤔 Where is pathogenic IgA produced❓ 👉🏻 B cells induced in MALT can migrate to the bone marrow and differentiate into IgA-PC there 💉💊 We have emerging therapies to target B cells in Ivan but we still need a better understanding of the pathophysiology #ISNWCN @theisn.org

🤔 Where is pathogenic IgA produced❓ 👉🏻 B cells induced in MALT can migrate to the bone marrow and differentiate into IgA-PC there 💉💊 We have emerging therapies to target B cells in Ivan but we still need a better understanding of the pathophysiology #ISNWCN @theisn.org